Sellas' Galinpepimut-S Immunotherapy Study to End in Failure
核心洞察
Sellas Life Sciences' experimental immunotherapy galinpepimut-S is predicted to fail to prolong survival versus standard treatment in acute myeloid leukemia (搜索) patients in second remission.
The event-driven Phase 3 REGAL study has already been delayed by nearly a year, which raises significant doubts about the efficacy of the Sellas treatment.
The prediction, published in a subscriber-only biotech newsletter, anticipates a negative outcome for REGAL, though the timing of that outcome remains unknown.
Sellas Life Sciences Group's experimental immunotherapy galinpepimut-S (GPS) is predicted to fail to prolong survival compared with standard treatment in patients with acute myeloid leukemia (搜索) in a second remission. The prediction anticipates a negative outcome for the company's Phase 3 REGAL study.
The event-driven study's conclusion has already been delayed by nearly a year, which raises significant doubts about the efficacy of the Sellas treatment. While the negative outcome is expected, the timing of when it will occur remains unknown.
The assessment was published in Adam's Biotech Scorecard, a subscriber-only newsletter.